Biomarkers of fibrosis, inflammation, and extracellular matrix in the phase 3 trial of tocilizumab in systemic sclerosis.

Sheng, X Rebecca; Gao, Xia; Schiffman, Courtney; Jiang, Jenny; Ramalingam, Thirumalai R; Lin, Celia J F; Khanna, Dinesh; Neighbors, Margaret

Sheng, X Rebecca; Gao, Xia; Schiffman, Courtney; Jiang, Jenny; Ramalingam, Thirumalai R; Lin, Celia J F; Khanna, Dinesh; Neighbors, Margaret.

Sheng XR; Genentech Inc., South San Francisco, CA, United States of America. Electronic address: shengx@gene.com.
Gao X; Genentech Inc., South San Francisco, CA, United States of America.
Schiffman C; Genentech Inc., South San Francisco, CA, United States of America.
Jiang J; Genentech Inc., South San Francisco, CA, United States of America.
Ramalingam TR; Genentech Inc., South San Francisco, CA, United States of America.
Lin CJF; Genentech Inc., South San Francisco, CA, United States of America.
Khanna D; University of Michigan Scleroderma Program, Division of Rheumatology/Department of Internal Medicine, Ann Arbor, MI, United States of America.
Neighbors M; Genentech Inc., South San Francisco, CA, United States of America. Electronic address: neighbom@gene.com.

Clin Immunol ; 254: 109695, 2023 09.

Article en En | MEDLINE | ID: mdl-37479123

Asunto(s)

Esclerodermia Sistémica; Humanos; Esclerodermia Sistémica/tratamiento farmacológico; Fibrosis; Biomarcadores; Matriz Extracelular; Inflamación

Palabras clave

Biomarkers; Fibrosis; IL-6; Systemic sclerosis; Tocilizumab

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esclerodermia Sistémica Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esclerodermia Sistémica Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article